- Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials2019 | Second Faculty of Medicine
- Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials2011 | Second Faculty of Medicine
- Use of the antibiotic ceftazidime / avibactam in the treatment of severe pulmonary exacerbation in a patient with cystic fibrosis2020 | Second Faculty of Medicine
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)2014 | Second Faculty of Medicine
- Laboratory biomarkers for lung disease severity and progression in cystic fibrosis2020 | Second Faculty of Medicine
- Changes in the lung bacteriome in relation to antipseudomonal therapy in children with cystic fibrosis2018 | Second Faculty of Medicine, Faculty of Mathematics and Physics
- The future of cystic fibrosis care: a global perspective2020 | Second Faculty of Medicine
- The current view of the diagnosis and new treatment options of Cystic Fibrosis2016 | Faculty of Medicine in Pilsen
- Examination of exhaled breath condensate in cystic fibrosis2010 | Second Faculty of Medicine
- Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view2020 | Second Faculty of Medicine
- Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues2024 | Second Faculty of Medicine, Central Library of Charles University
- Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR2015 | Second Faculty of Medicine
- Lung function in a group of Czech infants with cystic fibrosis2019 | Second Faculty of Medicine
- Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele2019 | Second Faculty of Medicine